L-tyrosine is an amino acid the body uses to make dopamine and norepinephrine — the neurotransmitters most involved in alertness, motivation, and working memory. The evidence for it is a genuinely interesting case: it is one of the more mechanistically well-supported "focus" amino acids, but the benefit it shows in trials is conditional, not universal.

The core finding: it helps when you're depleted, not at baseline

Jongkees et al. (2015), a systematic review, concluded that tyrosine supplementation improves cognitive performance specifically in situations that deplete catecholamines (dopamine and norepinephrine) — such as acute stress, cold exposure, sleep deprivation, or heavy multitasking — but does not reliably improve performance in people who are rested and not under those demands. That single distinction is the honest headline for this ingredient.

What the human trials actually tested

  • Colzato et al. (2013) gave healthy young adults roughly 2 g of tyrosine before a working-memory (N-back) task and found improved working-memory updating versus placebo — a cognitively demanding, taxing task, not a rested baseline measure.
  • Sleep-deprivation and cold-stress studies in the wider literature have used considerably higher doses, in the range of 100–150 mg/kg (roughly 7–12 g for an average adult) — doses well above the ~2 g used in single-session cognitive trials, and studied in more extreme physical-stress paradigms such as military and cold-exposure research.

Where it doesn't seem to help

In rested, unstressed, well-fed adults performing undemanding tasks, tyrosine supplementation has not reliably shown a performance benefit over placebo. The mechanism explains why: if catecholamine levels are already adequate, adding more of their precursor amino acid has less to correct. This is the opposite framing of a stimulant, which tends to act regardless of baseline state.

Form matters: plain tyrosine versus NALT

N-Acetyl-L-Tyrosine (NALT) is often marketed as a more "advanced" or better-absorbed form. The available pharmacokinetic evidence points the other way: NALT converts poorly to usable tyrosine when taken orally and raises plasma tyrosine levels far less than the same milligram amount of plain, free-form L-tyrosine. Nearly all of the positive human cognition and stress trials used plain L-tyrosine, not NALT — a distinction worth checking on a label.

Who should check with a clinician first

  • Anyone taking an MAOI antidepressant — this combination is contraindicated due to hypertensive-crisis risk, since tyrosine is a precursor in the same pathway MAOIs affect.
  • Hyperthyroidism or Graves' disease — tyrosine is a precursor to thyroid hormone synthesis; review with a clinician first.
  • Pregnant or breastfeeding — not established as safe in this population; the conservative position is to avoid without clinician guidance.
  • History of melanoma — tyrosine is also a precursor in melanin synthesis; a reason for clinician review, not necessarily avoidance.
  • Taking levodopa for Parkinson's disease — tyrosine and levodopa can compete for absorption; doses should be separated and discussed with the prescriber.

How to think about it

L-tyrosine has a real, mechanistically coherent, and reasonably well-supported use case: protecting cognitive performance when stress, sleep loss, cold, or heavy task demand would otherwise deplete catecholamines. It is not well supported as a general everyday enhancer for someone who is already rested and unstressed, and the specific dose and form on a label matter more than the ingredient name alone.

References

  • Jongkees BJ, Hommel B, Kühn S, Colzato LS. "Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands—A review." Journal of Psychiatric Research, 2015;70:50–57. PMID: 26424423.
  • Colzato LS, Jongkees BJ, Sellaro R, Hommel B. "Working memory reloaded: tyrosine repletes updating in the N-Back task." Frontiers in Behavioral Neuroscience, 2013;7:200. PMID: 24379768.